GRT-C903
- Generic Name
- GRT-C903
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Phase 1
Recruiting
- Conditions
- Non-Small Cell Lung CancerGastrointestinal CancerOvarian CancerMetastatic Solid CancersColorectal CancerBreast CancerGenitourinary Cancer
- Interventions
- Biological: KRAS TCR-Transduced PBL
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 210
- Registration Number
- NCT06253520
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath